chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Weakness; Nerve pain; Soreness; I have had to miss work and alter my lifestyle; Numbness; This spontaneous case was reported by a patient and describes the occurrence of ASTHENIA (Weakness), NEURALGIA (Nerve pain), PAIN (Soreness), LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (I have had to miss work and alter my lifestyle) and HYPOAESTHESIA (Numbness) in a  patient of an unknown age and gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    In October 2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced ASTHENIA (Weakness), NEURALGIA (Nerve pain), PAIN (Soreness), LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (I have had to miss work and alter my lifestyle) and HYPOAESTHESIA (Numbness). At the time of the report, ASTHENIA (Weakness), NEURALGIA (Nerve pain), PAIN (Soreness) and HYPOAESTHESIA (Numbness) had not resolved and LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (I have had to miss work and alter my lifestyle) outcome was unknown.     Concomitant Medication use information was not provided by reporter. It was reported that the patient received Moderna booster 2 weeks ago. Treatment Medication use information was not provided by reporter.
Patient had a positive COVID test on 2/7/2022,  admitted to the hospital on 2/14/2022, and expired on 3/2/2022.
Information has been received from a physician concerning a 14-month-old female with no medical history who on 08-JUN-2006 was vaccinated SC in the left thigh with the first dose of measles virus vaccine live (+) mumps virus vaccine live (+) rubella virus vaccine live (+) varicella virus vaccine live (Lot#651812/0769R). There was no illness at the time of vaccination. The physician reported that on approximately 13-JUN-2006 the patient developed a blistery rash which subsequently resolved. On 05-JUL-2006 the patient developed papules, which increased in number by 07-JUL-2006. On that same day, the patient was seen by the physician. At the same time she had papules and vesicles with an erythematous base typical of wild type varicella. The physician felt that the patient had been exposed to wild type varicella shortly before or after vaccination. On 12-JUL-2006, the patient was seen by another physician who confirmed she had resolving varicella and gave her some samples of Cedax to cover for possible secondary infection and noted that she has passed the contagious phase. The patient's wild type varicella was diagnosed clinically as no diagnostic work up (no titers drawn) was done to confirm the diagnosis. As of 18-JUL-2006, the patient's wild type varicella was noted to be resolved. The physician thought the patient's current case of chickenpox was wild type and due to breakthrough and was not related to vaccination with measles virus vaccine live (+) mumps virus vaccine live (+) rubella virus vaccine live (+) varicella virus vaccine live (Lot#651812/0769R) and was unsure if the patient's previous "blistery" rash was due to the vaccine but suspected it was. No further information is available.
New rash localized to injection site that is red, raised, itchy, and hot to the touch. 7 cm in diameter. Patient had rash at site of injection for several days after the injection, however this initial rash disappeared within 3 days. The adverse event being reported is the new rash given the delayed reaction and allergic nature of the response.
7 days after having vaccine I had Covid symptomds on the 17th of Jan I tested positive for covid
I am experiencing gradual hair loss and shedding from the hair on my scalp that started 2 days after my first covid vaccination in February 2021 and has continued for the last 16 months.  I estimate I have lost about 40% of my hair.  Prior to the vaccination my scalp hair was quite thick, but it is thin now. Although the hair shedding slowed somewhat 6 months after my first vaccination, it started up again at the same rate when I got a flu shot and covid booster shot in October 2021.  The hair shedding is still ongoing, and it doesn't look like there is new hair growth to replace it.   I do not know how to encourage new hair growth.  Is there any treatment for this?  Could I lose ALL my hair? 
Information has been received from a physician concerning a 19 year old female who was vaccinated with a first dose of the Gardasil on an unspecified date. Subsequently, the patient developed a fever of 102 degrees, was vomiting for 24 hours and did not feel well for three days. At the time of the report, the patient had recovered. It was also reported that the patient received the second dose of the Gardasil on an unspecified date, and "she was feeling fine after receiving the" vaccination. Additional information has been requested. 10/08/07 This is in follow-up to report(s) previously submitted on 7/16/2007. Initial and follow-up information has been received from a physician concerning a 19 (also reported as 18) year old female with no pertinent medical history or drug reactions/allergies who on 21-SEP-2006 was vaccinated with a first dose of the GARDASIL (lot # unknown) in the arm at 10:30 AM. On 21-SEP-2006 at 10:00 PM, the patient developed a fever of 102 degrees for 24 hours, was vomiting for 24 hours and overall did not feel well for three days after the injection. At the time of the report, the patient had recovered. It was also reported that the patient received the second dose of the GARDASIL on an unspecified date and "she was feeling fine after receiving the vaccination". Additional information has been requested.
COVID-19 treatment; COVID-19 treatment; This is a spontaneous report received from a contactable reporter(s) (Physician) from Regulatory Authority.  A 68-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 12Jan2022 as dose 1, single (Batch/Lot number: unknown) and on 02Feb2022 as dose 2, single (Batch/Lot number: unknown) at the age of 67 years for covid-19 immunisation. The patient's relevant medical history included: "Hypothyroidism" (unspecified if ongoing). Concomitant medication(s) included: LEVOTHYROXINE. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset May2022, outcome "unknown" and all described as "COVID-19 treatment". Therapeutic measures were taken as a result of vaccination failure, covid-19.  Clinical course- The patient receive any other vaccines within 4 weeks prior to the COVID vaccine. There was list of other medications the patient received within 2 weeks of vaccination. Nasal congestion and post nasal drip and had positive covid test again 02Jun2022 but was negative.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
On 6/24/2021 I woke up with gastral issues, which subsided late in the evening of 6/25/2021. On 6/26 went back to my normal  routine and worked out in the gym and 6/27 played basketball for 2 plus hours. I was fatigued on 6/28 and 6/29. On 6/30 still fatigued went to the gym and did a light cardio workout and developed a heat rash on buttock and upper thighs. I took a Benadryl which cured the heat rash.  on 7/1 in the evening I developed a dry cough that was pretty intense. At this time I noticed my eye sight was blurry at a distance. 7/2 the cough went away, Looking back I now notice I had balance issues on 7/2. On 7/3 eyesight was worse and I was seeing double.  I went and had an eye exam and the Dr. thought I may have a retinal issue in my left eye and suggested I go to the hospital which I did.
Injection site swollen, pain radiated up neck and down arm--had muscle spasms in affected side hand.
This spontaneous report was received from a pharmacist and refers to a patient of unknown age and gender. Information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant medications was not provided. On unknown dates, the patient was vaccinated with two doses of PNEUMOVAX 23 (dose, route of administration, lot number and expiration date were not reported). No adverse effects were reported. No product quality complaint was involved.
pt recvd vax & exp bumpy rash on arms; Pt did not seek treatment; pt recvd 2nd dose of vax w/o any problems;
Swelling, redness, and pain on R deltoid. Treating with anti-histamines.
minor swelling at injection site; redness at injection site; pain at injection site; This case was reported by a consumer via call center representative and described the occurrence of injection site swelling in a 78-year-old female patient who received Flu unspecified (Flu vaccine) for prophylaxis.   In December 2018, the patient received the 1st dose of Flu vaccine. On an unknown date, unknown after receiving Flu vaccine, the patient experienced injection site swelling, injection site erythema and injection site pain. On an unknown date, the outcome of the injection site swelling, injection site erythema and injection site pain were unknown.   It was unknown if the reporter considered the injection site swelling, injection site erythema and injection site pain to be related to Flu vaccine.  Additional details were provided as follows: After receiving flu vaccine the patient experienced injection site swelling, injection site erythema, injection site pain. Did not consent to follow-up. This case has been linked to case US2019060766 reported by same reporter.
lost memory for half an hour; feel confused; This spontaneous case was reported by a consumer and describes the occurrence of AMNESIA (lost memory for half an hour) and CONFUSIONAL STATE (feel confused) in a 48-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 045B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 01-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-May-2021, the patient experienced AMNESIA (lost memory for half an hour) and CONFUSIONAL STATE (feel confused). At the time of the report, AMNESIA (lost memory for half an hour) and CONFUSIONAL STATE (feel confused) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The patient took blood pressure, cholesterol and thyroid pills. No treatment details were provided.
started itching; 3" X 1" rash over the injection site; still feels sore; exhausted, and stayed in bed; started feeling nauseous; vomiting; feeling weird; This spontaneous case was reported by a consumer and describes the occurrence of FEELING ABNORMAL (feeling weird), VACCINATION SITE PRURITUS (started itching), NAUSEA (started feeling nauseous), VOMITING (vomiting) and VACCINATION SITE RASH (3" X 1" rash over the injection site) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 010A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 04-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Mar-2021, the patient experienced FEELING ABNORMAL (feeling weird), NAUSEA (started feeling nauseous) and VOMITING (vomiting). On 06-Mar-2021, the patient experienced FATIGUE (exhausted, and stayed in bed). On 07-Mar-2021, the patient experienced VACCINATION SITE PRURITUS (started itching), VACCINATION SITE RASH (3" X 1" rash over the injection site) and VACCINATION SITE PAIN (still feels sore). On 05-Mar-2021, NAUSEA (started feeling nauseous) and VOMITING (vomiting) had resolved. On 07-Mar-2021, FATIGUE (exhausted, and stayed in bed) had resolved. At the time of the report, FEELING ABNORMAL (feeling weird), VACCINATION SITE PRURITUS (started itching) and VACCINATION SITE RASH (3" X 1" rash over the injection site) outcome was unknown and VACCINATION SITE PAIN (still feels sore) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       NO concomitant medication details were provided. No treatment information was provided.
Patient answered no to the screening questions for the flu mist. The flu mist was given prior to scanning the product. After administration and the flu mist was scanned, an error prompted a contraindication with flu mist and the methotrexate that the patient is currently taking.
Information has been received from a medical assistant concerning a female patient who in September 2010, was vaccinated with a first dose of HPV rL1 6 11 18 VLP vaccine (yeast) (dose, route and lot # not reported), in January 2011 was vaccinated with a second dose of HPV rL1 6 11 18 VLP vaccine (yeast) (dose, route and lot # not reported) and on 25-JAN-2012 was vaccinated with a third dose of HPV rL1 6 11 18 VLP vaccine (yeast) (dose, route and lot # not reported). No adverse effect was reported. Additional information has been requested.
chills, aching, loss of appetite, dizziness, flu-like sx requiring bed rest;
Child developed fever and full body rash. His mother brought him to the clinic the next morning. (06/03/2016) Child was coping well and recovered with oral Benadryl. He had a follow up with Dr. (06/06/2016) after my visit and was treated for an ear infection. Rash was still present but improved.
This is a spontaneous report from a Pfizer-sponsored program, from a non-contactable consumer. A patient of unspecified age, race, ethnicity and gender received PREVNAR 13 at single dose via an unspecified route of administration on an unspecified date for immunization. The patient medical history and concomitant medications were not reported. On an unspecified date after the vaccination the patient ended up in hospital with pneumonia. Outcome was unknown. No follow-up attempts are possible, information about batch number cannot be obtained.
Acute pain all the way down the R arm (ulnar nerve) in which the vaccine was administered. Pain was followed by numbness for approximately 12 hours. Also, acute nausea and gagging, sick to stomach for over 24 hours.
Immunizations given.  Within 2 minutes patient began vomiting and then progresses to wheezing and poor air exchange with a pulse ox reading of 80% within 2-3 minutes.  Color dusky.
Beyond 42 days since 1st dose of vaccine, She has not received the second dose due to health reasons.; nasal/sinus drainage; cough; This spontaneous case was reported by a consumer and describes the occurrence of RHINORRHOEA (nasal/sinus drainage), COUGH (cough) and PRODUCT DOSE OMISSION ISSUE (Beyond 42 days since 1st dose of vaccine, She has not received the second dose due to health reasons.) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Diabetic and Pollen allergy (severe sinus allergies due to the pollen).    In February 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced RHINORRHOEA (nasal/sinus drainage), COUGH (cough) and PRODUCT DOSE OMISSION ISSUE (Beyond 42 days since 1st dose of vaccine, She has not received the second dose due to health reasons.). At the time of the report, RHINORRHOEA (nasal/sinus drainage), COUGH (cough) and PRODUCT DOSE OMISSION ISSUE (Beyond 42 days since 1st dose of vaccine, She has not received the second dose due to health reasons.) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant information was reported. No treatment information was reported.   Most recent FOLLOW-UP information incorporated above includes: On 05-Aug-2021: Follow up information received contains significant information- Event outcome updated for the events rhinorrhoea and Cough from unknown to recovered/resolved. Duration of reaction added for the evets rhinorrhoea and cough.
In bed for a month; Initial information was received on 05-Nov-2021 regarding an unsolicited valid serious case received from a Social Media via a consumer/non-health care professional.  This case involves a patient (unknown demographics) who was in bed for a month (bedridden) after receiving INFLUENZA VACCINE.  The patient had no medical history, concomitant disease or risk factor.  The patient's past medical treatment(s), vaccination(s), concomitant medication(s) and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (batch number and expiry not reported) via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date the patient developed a serious in bed for a month (bedridden) (unknown latency) following the administration of INFLUENZA VACCINE. This event was leading to disability.  It was unknown if the patient experienced any additional symptoms/events.   There were no lab data/results available.  It was not reported if the patient received a corrective treatment for the event.  At time of reporting, outcome of the event was unknown.  Information on batch number was requested for this case.; Sender's Comments: This case concerns a patient (unknown demographics) who experienced bedridden after vaccination with INFLUENZA VACCINE produced by unknown manufacturer. The time to onset is unknown. Additional information regarding patient's past vaccination(s), vaccination tolerance, condition at the time of vaccination and laboratory data excluding other predisposing etiologies would be needed for complete assessment of the case. Based upon the reported information, the role of the vaccine cannot be assessed.
This spontaneous report as received from a pharmacist refers to about 30 unspecified patients of unknown demographics. The patients pertinent medical history, concurrent condition and concomitant medication were not reported. No previous drug reactions/allergies were reported. On unknown dates unspecified these patients were vaccinated with improperly stored ZOSTAVAX (lot # L017138 and expiration date 13-AUG-2016) (dosing details and anatomical location were unknown). No adverse effects were reported. No product quality complaint was involved. Additional information has been requested.
like purplish red color; size of a baseball; really red; Itching on the surface of her skin at the injection site; Burning on the surface of her skin at the injection site/sore; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE DISCOLOURATION (like purplish red color), VACCINATION SITE MASS (size of a baseball), VACCINATION SITE PRURITUS (Itching on the surface of her skin at the injection site), VACCINATION SITE PAIN (Burning on the surface of her skin at the injection site/sore) and VACCINATION SITE ERYTHEMA (really red) in a 36-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 0502C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-Jul-2021, the patient experienced VACCINATION SITE PRURITUS (Itching on the surface of her skin at the injection site) and VACCINATION SITE PAIN (Burning on the surface of her skin at the injection site/sore). On an unknown date, the patient experienced VACCINATION SITE DISCOLOURATION (like purplish red color), VACCINATION SITE MASS (size of a baseball) and VACCINATION SITE ERYTHEMA (really red). At the time of the report, VACCINATION SITE DISCOLOURATION (like purplish red color), VACCINATION SITE MASS (size of a baseball), VACCINATION SITE PRURITUS (Itching on the surface of her skin at the injection site), VACCINATION SITE PAIN (Burning on the surface of her skin at the injection site/sore) and VACCINATION SITE ERYTHEMA (really red) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were reported. No treatment information was provided.
An 11 year old patient was administered a PNEUMOVAX 23 vaccine by mistake instead of a T-Dap vaccine.; An 11 year old patient was administered a PNEUMOVAX 23 vaccine by mistake instead of a T-Dap vaccine.; An 11 year old patient was administered a PNEUMOVAX 23 vaccine by mistake instead of a T-Dap vaccine.; No symptomatic AEs. No additional AE details or PQC.; This spontaneous case has been received from a nurse concerning an 11-year-old patient of unknown gender.  The patient's pertinent medical history, concurrent conditions, previously drug reactions, allergies and concomitant medications were not provided.  On 15-JUN-2022, the patient was vaccinated with pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) injection for prophylaxis (dose, vaccination scheme frequency, route of administration, anatomical location, lot number and expiration date were not provided) (product administered to patient of inappropriate age). This was administered by mistake instead of a diphtheria vaccine toxoid, pertussis vaccine, tetanus vaccine toxoid (reported as T-Dap) vaccine (formulation, indication, dose, and vaccination scheme frequency were not reported) (wrong product administered, interchange of vaccine products). No symptomatic adverse events were reported.
Information has been received on 01-MAR-2019 regarding a case in litigation concerning a female patient (age unknown). The patient's medical history, concurrent conditions and concomitant medication use were not provided. The patient was prescribed ZOSTAVAX by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. In 2016, the patient was administered the ZOSTAVAX vaccine (lot# and route not specified) by a healthcare provider.  The patient was treated by a healthcare provider for shingles as a result of vaccination with ZOSTAVAX. The outcome was not provided. Additional information has been requested.
Approximately 24 hours after vaccine administration, patient noticed localized swelling within the muscle at the site of injection. There was notable absence of pain, redness, warmth, or fever. Palpable firmness deep within the muscle without tenderness, weakness, or pain. Took Ibuprofen at home and iced area. Presented to office on 1/11/17 for routine well check and had area assessed by Physician's Assistant.
First one couple days later gave edema in feet and ankles Second caused Edema and Neuropathy. Following immediately that evening and worsening each day and still going on.
pt recvd vax & devel redness of skin around inject site & hives around inject site; DPH given;
On Friday May 6th I had my second Moderna booster vaccine. On Saturday May 7th I had to stay in bed all day and night because I felt unwell. I had shivers, fever, my arm, at the injection site, was red and swollen and hot to the touch, my legs ached and I had restless leg syndrome (something I have never had before). I couldn't eat nor want any food, just drank plenty of water. Felt tired all day. By Monday May 9th I feel a lot better with no fever just fatigue. Took an at home Covid test and that was negative. My first Moderna booster back in November 2021, I had no reactions, except for a sore arm at the injection site.